Navigation Links
Genelex Corporation Defends Consumers' Right to Obtain DNA Information:
Date:1/9/2008

Company founder urges government to apply rating system to home DNA tests

to protect against 'unscrupulous and misrepresented tests'

WASHINGTON, Jan. 9 /PRNewswire/ -- Should consumers have a right to obtain information regarding their personal health through home DNA tests? According to Genelex founder, Howard Coleman, the answer is: absolutely. "I agree with scientific opinion that tens of thousands of lives can be saved each year by DNA testing that reveal potential adverse drug reactions."

Coleman believes that such specific and accurate information will be the foundation for personalized medical treatment in the 21st century. "One pill does not fit all," Coleman states.

Genelex Corporation sells home DNA tests that analyze an individual's ability to process the most commonly prescribed and over the counter medication. "More than half the population has DNA alterations that can render many medications ineffective, or worse, trigger side effects that can prove to be fatal," Coleman said. Some common medications depend upon an individual's DNA for effectiveness and safety include Tamoxifen, Coumadin, Codeine and many others.

Coleman testified Tuesday before the President's Council of Advisors on Science and Technology in Washington DC (http://www.ostp.gov/PCAST/pcast.html). While Coleman supports consumers' access to home DNA tests, he shares some of the Council's concerns that there are unscrupulous companies that don't provide accurate or useful testing. Coleman suggested that companies who sell home DNA tests should, in cooperation with government agencies, implement a rating system that describes the certainty of their predictive value. "People have a fundamental right to learn and control this information. A rating system would allow people to decide if a particular test meets their needs."

Genelex Corporation was founded in 1987, and provides a program for comprehensive personalized medication management consisting of DNA testing and software for interpreting the test results based on all of the medicines a patient is taking.

For further information about Genelex go to http://www.Genelex.com. To contact Howard Coleman, call (206) 714-6393.


'/>"/>
SOURCE Genelex Corporation
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Memry Corporation Announces Preliminary Fiscal Fourth Quarter and 2007 Revenue
2. PeriCor Therapeutics Announces Closing of Licensing Agreement for Acadesine with Schering-Plough Corporation
3. AGA Medical Corporation Receives FDA and CE Mark Approvals for the AMPLATZER Vascular Plug II
4. Drug Royalty Corporation (DRC) Announces Acquisition Regarding PEG-INTRON(R) From Enzon Pharmaceuticals, Inc. (ENZN)
5. BioElectronics Corporation Announces Singapore and Malaysia Sales
6. Avicena Signs Worldwide Exclusive Distribution Agreement with RITA Corporation for its Proprietary Dermaceutical Compounds
7. DURECT Corporation to Present at the NewsMakers in the Biotech Industry Investment Conference
8. Insulet Corporation to Present at the Thomas Weisel Partners Healthcare Conference on September 6, 2007
9. Luminex Corporation to Present at Thomas Weisel Partners Healthcare Conference
10. Verenium Corporation to Present at the Upcoming Cowen and Company Clean Energy Conference
11. Enova Medical Launches Exos Corporation
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/16/2017)... ... January 16, 2017 , ... Appellate Court of New ... the appeal filed by India-based Dishman Pharmaceutical & Chemical Ltd. company (DPCL) for ... one of its Dishman Group’s 100% wholly owned New Jersey-based subsidiary Dishman USA ...
(Date:1/16/2017)... , Jan. 16, 2017  Eurofins Genomics today announced ... allow more customers to receive their primers in a ... compromise in quality found with other providers. Express oligos ... States at no additional fee. ... genetic studies, including DNA sequencing, genotyping, site-directed mutagenesis, and ...
(Date:1/13/2017)... Jan 13, 2017 Research and Markets has ... Application - Global Forecast to 2021" report to their offering. ... The biosimilars ... USD 3.39 Billion in 2016, at a CAGR of 26.3%. ... of product, manufacturing type, and application. Factors such as rising incidence ...
(Date:1/13/2017)... , ... January 13, 2017 , ... ... cuvette-related demand that it has found among its diverse customer base. The latest ... use in most brands electroporators including BTX and Bio-Rad. FireflySci is introducing three ...
Breaking Biology Technology:
(Date:1/6/2017)... 5, 2017  Delta ID Inc., a leader in ... for automotive at CES® 2017. Delta ID has collaborated ... demonstrate the use of iris scanning as a secure, ... driver in a car, and as a way to ... Delta ID and Gentex will demonstrate (booth ...
(Date:12/22/2016)... 20, 2016  As part of its longstanding mission to ... genetics company, recently released its latest children,s book, titled ... focuses on the topics of inheritance and variation of traits ... taught in elementary school classrooms in the US. ... illustrator Ariana Killoran , whose previous book with 23andMe, ...
(Date:12/19/2016)... , España y TORONTO , 19 de ... con Northern Biologics Inc. que permitirá el desarrollo acelerado de MSC-1, ... clínicos en varios tipos de tumor en 2017, con múltiples sitios ... ... su clase con objetivo en el factor inhibidor de leucemia (LIF), ...
Breaking Biology News(10 mins):